FDA grants priority review of new use for Pfizer's Xalkori; U.K. patients get AZ's Tagrisso under early access scheme;

> The FDA has granted a priority review of Pfizer's ($PFE) Xalkori for the treatment of patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive. Release

> AstraZeneca's ($AZN) lung cancer treatment Tagrisso has become the fourth med to be made available to U.K. patients before approval under an early access scheme. Report

> Baxalta ($BXLT) has won FDA approval for a drug that treats Von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein. Report

> India's Aurobindo Pharma has received an FDA green light to manufacture and market its oral contraceptive Levonorgestrel tablets. Report

> Johnson & Johnson's ($JNJ) Janssen has submitted an application to the EMA for use of Stelara in adults with severe active Crohn's disease. Report

And Finally... The acute myeloid leukemia (AML) drug market will expand to $932.6 million by 2024 from $342.7 million in 2014, research and consulting firm GlobalData says. More

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.